Bioxytran's Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19

Stock Information for Ampio Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Ampio Pharmaceuticals Inc.

Presenting on the Emerging Growth Conference 70 Day 1 on May 8 Register Now
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now
Bioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 Antagonist
Bioxytran Gets Broad Patent Coverage on 60+ Viruses
Bioxytran Interview at the Emerging Growth Conference
Bioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-M
Bioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical Trials
Bioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 Patients

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.